Comparing Nivolumab and Platinum-Based Chemotherapy in Non-Small-Cell Lung Cancer

Overview of Treatment Options

Evaluating the efficacy of the immunotherapy inhibitor nivolumab against platinum-based chemotherapy is crucial for oncologists in identifying the most beneficial first-line treatment for patients with advanced or recurrent non-small-cell lung cancer (NSCLC). Platinum-based chemotherapy utilizes complexes of the metal platinum, which, while primarily aimed at targeting tumor cells, can also adversely affect normal cells, leading to side effects such as hearing loss, hair loss, kidney damage, and nerve damage.

Limitations of Platinum-Based Chemotherapy

As a standard first-line treatment, platinum-based chemotherapy involves a dual-drug strategy designed to target cancer cells lacking mutations responsive to targeted therapies. However, in advanced cases of NSCLC, this approach has shown only moderate effectiveness and a limited safety profile.

Nivolumab’s Advantages

In contrast, nivolumab, a programmed death ligand-1 (PD-L1) immune checkpoint inhibitor, has demonstrated significant benefits, particularly for patients expressing PD-L1, especially those with elevated PD-L1 levels. Clinical studies indicate that nivolumab therapy can extend survival for patients with NSCLC.

Importance of Clinical Trials for NSCLC

Understanding Non-Small-Cell Lung Cancer

NSCLC encompasses various types, including bronchoalveolar, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Factors such as firsthand and secondhand smoke, asbestos exposure, radon, and environmental agents contribute to lung cancer development. Given that NSCLC accounts for over 85% of lung cancer cases, improving treatment for this chemo-insensitive disease is vital for enhancing the current 14% five-year survival rate in advanced cases. Consequently, clinical trials exploring new drugs and treatment methodologies for NSCLC are essential.

Clinical Trials Comparing Nivolumab and Platinum-Based Chemotherapy

Phase-3 Clinical Trials Findings

In two phase-3 clinical trials, researchers assessed the effectiveness of nivolumab versus platinum-based chemotherapy, with their findings published in The New England Journal of Medicine. The trials revealed that nivolumab significantly improved overall survival in patients with metastatic NSCLC experiencing disease progression during or after chemotherapy compared to the platinum-based drug docetaxel. This prompted a comprehensive international randomized, open-label, phase-3 trial where patients with stage 4 or recurrent NSCLC were randomly assigned to receive either nivolumab (3 mg/kg body weight) biweekly or platinum doublet chemotherapy every three weeks for four to six cycles, involving 423 participants with a PD-L1 expression level of 5% or 1%.

Results of Nivolumab vs. Platinum-Based Treatment

The results indicated that patients with a PD-L1 expression level of 5% or higher had a median progression-free survival of 4.2 months with nivolumab, compared to 5.9 months for the platinum-based therapy group. The overall survival was recorded at 14.4 months for nivolumab, with adverse effects reported in 71% of these patients, while the platinum-based group had an overall survival of 13.2 months with adverse effects in 92% of participants. Although nivolumab exhibited a favorable safety outcome, it did not significantly prolong progression-free survival compared to chemotherapy, and overall survival rates were similar between the two groups.

Nivolumab’s Broader Benefits

Nivolumab has shown benefits regardless of PD-L1 expression and is particularly effective for patients with non-squamous NSCLC and higher PD-L1 levels. Although platinum-based drugs remain the primary standard-of-care therapy, their notable toxicity plays a role in poor treatment outcomes for NSCLC. As an immunotherapy option recognized for its favorable safety profile and improved long-term survival rates, nivolumab presents a promising treatment avenue for patients with advanced or recurrent non-small-cell lung cancer.

Reference

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators. N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.